At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 610 enrolled
Drug / intervention
PN 400 (VIMOVO) +3 moredrug
Likely dose
PN 400 (VIMOVO) 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Center Study Evaluating the Efficacy of PN400 (VIMOVO) Twice Daily (Bid) and Celecoxib Once Daily (qd) in Patients With Osteoarthritis of the Knee
In Brief
A Phase 3 clinical trial evaluating PN 400 (VIMOVO), celebrex, and 2 other interventions for Osteoarthritis. Completed, enrolled 610 participants across 1 site.
Detailed Summary
We will evaluate the efficacy of PN 400 and an active comparator in patients that have Osteoarthritis of the knee.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2008
First PostedApr 2008
Primary CompletionDec 2008
Study CompletionJan 2009
TodayJul 2026
First PostedApr 23, 2008
Enrollment StartApr 1, 2008
Primary CompletionDec 1, 2008
Study CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 18.2 years ago
Interventions
PN 400 (VIMOVO)drug
500 mg naproxen/20 mg esomeprazole bid
celebrexdrug
200 mg celecoxib qd
Placeboother
sugar pill bid
Rescue Antaciddrug
Antacid Tablets